30,570 Shares in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Acquired by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. acquired a new stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 30,570 shares of the company's stock, valued at approximately $1,218,000. Avantax Advisory Services Inc. owned 0.85% of Aligos Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in the business. AlphaMark Advisors LLC increased its position in Aligos Therapeutics by 1,000.0% in the 4th quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company's stock valued at $44,000 after acquiring an additional 1,000 shares during the period. Golden State Wealth Management LLC acquired a new position in shares of Aligos Therapeutics in the fourth quarter valued at approximately $107,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Aligos Therapeutics by 19.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company's stock valued at $569,000 after purchasing an additional 2,306 shares during the period. Finally, Drive Wealth Management LLC purchased a new stake in shares of Aligos Therapeutics during the fourth quarter worth approximately $916,000. 60.43% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright lowered their price objective on shares of Aligos Therapeutics from $75.00 to $70.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th.

Remove Ads

Aligos Therapeutics Trading Up 9.2 %

Shares of NASDAQ:ALGS traded up $0.99 during midday trading on Wednesday, hitting $11.75. The stock had a trading volume of 127,580 shares, compared to its average volume of 171,098. The company has a market capitalization of $71.84 million, a PE ratio of -0.88 and a beta of 2.52. Aligos Therapeutics, Inc. has a 1 year low of $6.76 and a 1 year high of $46.80. The stock has a 50 day moving average price of $22.97 and a two-hundred day moving average price of $20.46.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last issued its earnings results on Monday, March 10th. The company reported ($13.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.63) by ($10.45). Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The business had revenue of $0.63 million for the quarter, compared to analysts' expectations of $0.43 million. During the same period last year, the company posted ($5.50) earnings per share. As a group, equities analysts expect that Aligos Therapeutics, Inc. will post -10.36 EPS for the current year.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).